Equities

Castle Biosciences Inc

CSTL:NMQ

Castle Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)18.93
  • Today's Change-1.28 / -6.33%
  • Shares traded761.76k
  • 1 Year change-8.95%
  • Beta1.1123
Data delayed at least 15 minutes, as of Mar 10 2025 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments293243259
Total Receivables, Net513823
Total Inventory8.147.943.98
Prepaid expenses7.676.296.21
Other current assets, total------
Total current assets360296292
Property, plant & equipment, net633826
Goodwill, net111111
Intangibles, net96107116
Long term investments------
Note receivable - long term0.921.191.09
Other long term assets1.231.441.11
Total assets531453447
LIABILITIES
Accounts payable6.90104.73
Accrued expenses383429
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.380.070.15
Other current liabilities, total3.663.481.82
Total current liabilities494836
Total long term debt100.030.09
Total debt100.100.24
Deferred income tax1.610.210.43
Minority interest------
Other liabilities, total141412
Total liabilities756248
SHAREHOLDERS EQUITY
Common stock0.030.030.03
Additional paid-in capital656609560
Retained earnings (accumulated deficit)(200)(218)(161)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.230.14(0.38)
Total equity456391399
Total liabilities & shareholders' equity531453447
Total common shares outstanding282727
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.